Search research articles
Contact Us
Filters
Showing results (21-30 of 28) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 28 results.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
April 9, 2008
A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer
Kimberly A Chianese-Bullock, William P Irvin, Gina R Petroni, et al.
The Journal of Biological Chemistry
|
October 26, 2001
Lack of correlation between caspase activation and caspase activity assays in paclitaxel-treated MCF-7 breast cancer cells
Timothy J Kottke, April L Blajeski, X Wei Meng, et al.
Cancer Research Communications
|
June 26, 2024
A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170)
Edward Maldonado, W Kimryn Rathmell, Geoffrey I Shapiro, et al.
Oncotarget
|
April 19, 2017
A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma
Priscila H Goncalves, Lance K Heilbrun, Michael T Barrett, et al.
Molecular Cancer Therapeutics
|
June 12, 2015
Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non-V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team
Patricia M LoRusso, Scott A Boerner, Mary Jo Pilat, et al.
Cancer
|
February 7, 2025
Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)- and IDH2-mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial
Michael Cecchini, Mary Jo Pilat, Nataliya Uboha, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 5, 2016
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors
Patricia M LoRusso, Jing Li, Angelika Burger, et al.
Plos One
|
April 7, 2021
Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial
Patricia M LoRusso, Aleksandar Sekulic, Jeffrey A Sosman, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 28) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 28 results.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
April 9, 2008
A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer
Kimberly A Chianese-Bullock, William P Irvin, Gina R Petroni, et al.
The Journal of Biological Chemistry
|
October 26, 2001
Lack of correlation between caspase activation and caspase activity assays in paclitaxel-treated MCF-7 breast cancer cells
Timothy J Kottke, April L Blajeski, X Wei Meng, et al.
Cancer Research Communications
|
June 26, 2024
A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170)
Edward Maldonado, W Kimryn Rathmell, Geoffrey I Shapiro, et al.
Oncotarget
|
April 19, 2017
A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma
Priscila H Goncalves, Lance K Heilbrun, Michael T Barrett, et al.
Molecular Cancer Therapeutics
|
June 12, 2015
Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non-V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team
Patricia M LoRusso, Scott A Boerner, Mary Jo Pilat, et al.
Cancer
|
February 7, 2025
Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)- and IDH2-mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial
Michael Cecchini, Mary Jo Pilat, Nataliya Uboha, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 5, 2016
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors
Patricia M LoRusso, Jing Li, Angelika Burger, et al.
Plos One
|
April 7, 2021
Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial
Patricia M LoRusso, Aleksandar Sekulic, Jeffrey A Sosman, et al.
Page
of 3